Infosys and Telstra Announce Joint Venture in Australia
BENGALURU, India and MELBOURNE, Australia, Aug. 13, 2025 /CNW/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the formation of a joint venture with Telstra, Australia's leading telecommunications and technology company. Accelerating Infosys' strategy to help clients navigate their AI journey, this collaboration will propel AI-enabled cloud and digital solutions for Australian businesses.
Infosys will acquire 75% of the shareholding in Versent Group 1, Australia's leading Digital Transformation Solutions Provider, and a wholly owned subsidiary of Telstra Group, that delivers cloud and digital transformation. Infosys will have operational control, while Telstra will continue to retain a 25% minority stake in Versent Group, reflecting its confidence in the shared potential for growth and customer value, combining Telstra's connectivity, Versent's local digital engineering expertise, and Infosys' global scale.
Versent Group has earned its reputation by helping Australian enterprises design and implement cloud strategy with industry leading partners – delivering digital transformation with deep industry expertise. With a team of 650 engineers, advisors, strategists spread across Australia, Versent Group strengthens Infosys' local presence. Versent Group primarily serves large blue-chip organizations with established presence in government & education, financial institutions, energy, and the utilities sector.
This strategic collaboration will see Versent Group's cloud and digital transformation expertise boosted by Infosys' advanced AI capabilities, Cloud, Data and Digital consulting services. The collaboration will leverage Infosys Topaz and cloud offering Infosys Cobalt, as well as the cybersecurity capabilities of The Missing Link. It aims to deliver a new wave of differentiated value to accelerate end-to-end digital transformation for Australian enterprises and government corporations.
In 2024, Infosys had announced a strategic multi-year collaboration with Telstra to accelerate its software engineering and IT transformation journey and enhance customer experience. Further, in 2025, Infosys announced a collaboration with Telstra International, to advance technology leadership, drive innovation and support Telstra's new Connected Future 30 strategy. This joint venture is another key step in strengthening the strategic collaboration between the two organizations to further the technology transformation agenda for enterprises across the region.
Vicki Brady, Chief Executive Officer, Telstra said, "Our collaboration with Infosys reflects our confidence in the value we can unlock together. Their global scale, deep industry knowledge, and culture of innovation and service excellence will be instrumental in accelerating Versent Group's growth and impact across the region."
Salil Parekh, Chief Executive Officer, Infosys said, "We are excited to bring Infosys Topaz™ to enable transformative AI-first capabilities to complement Versent Group's cloud-first digital foundation. Expanding our trusted collaboration with Telstra, with whom we share a valued relationship, unveils a new opportunity to further accelerate the innovation agenda for enterprises across the region."
Oliver Camplin-Warner, Group Executive for Telstra Enterprise added, "We're excited about what's ahead as we deepen our strategic collaboration with Infosys. By combining the strengths of our three businesses, we're creating a unique proposition that will help Australian enterprises grow and innovate in today's fast-moving, AI-driven digital landscape."
Anand Swaminathan, Executive Vice President – Global Head of Communications, Media & Technology, Infosys added, "By combining Infosys' global leadership in digital services with the strength and trust of the Telstra brand, we are uniquely positioned to deliver cloud and AI solutions that are secure, resilient, and built for the digital needs of Australia and New Zealand. This collaboration reflects our shared commitment in accelerating AI-led innovation, and enabling a more connected, intelligent, and digital future for the region."
Infosys is delighted to welcome Versent Group and its leadership team.
The transaction is expected to close during the second half of FY 2026, subject to regulatory approvals and customary closing conditions.
1 Versent Group is Telstra Purple Pty Ltd and is the integration of Versent, Epicon, Telstra Purple Digital and associated Cloud Access products. Telstra Purple Digital refers to carve-out from Telstra's Enterprise Tech Services/Telstra Purple portfolio, and excludes Alliance Automation Pty Ltd, Aqura Technologies Pty Ltd, and Telstra Broadcast Services Pty Limited.
About Telstra
Telstra is Australia's leading telecommunications and technology company, delivering advanced connectivity across mobile, fixed, and digital platforms. We enable people, businesses, and governments to connect to what matters most—locally and globally. Through innovation and network leadership, we're building a more resilient, responsive, and inclusive digital future.
About Versent Group
Versent Group is a market leading digital transformation partner, uniting the capabilities of Versent, Telstra Purple Digital, and Epicon under one brand. With deep expertise in cloud-native solutions and a commitment to delivering real outcomes, Versent Group is focused on helping organisations achieve lasting success in a simpler, stronger way.
About Infosys
Infosys is a global leader in next-generation digital services and consulting. Over 320,000 of our people work to amplify human potential and create the next opportunity for people, businesses, and communities. We enable clients in 59 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.
Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.
Safe Harbor
Certain statements in this release concerning our future growth prospects, or our future financial or operating performance, are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, increased competition for talent, our ability to attract and retain personnel, increase in wages, investments to reskill our employees, our ability to effectively implement a hybrid work model, economic uncertainties and geo-political situations, technological disruptions and innovations such as artificial intelligence ("AI"), generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, and cybersecurity matters. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2025. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
1 Brilliant Quantum Computing Stock to Buy Before It Soars 70%, According to 1 Wall Street Analyst
Key Points IonQ is taking a unique approach to quantum computing. Quantum computing is expected to reach a turning point around 2030. 10 stocks we like better than IonQ › Wall Street analysts often give one-year price targets for stocks as a guide to where they think the stock is heading. While these projections are inherently flawed and in no way guarantee what will happen to a stock, understanding what the general analyst community thinks about a stock can be helpful in shaping your own research, especially in an area like quantum computing where there's a lot of hype. Kevin Garrigan from Rosenblatt Security recently set a new price target for quantum computing pure play IonQ (NYSE: IONQ). As of Wednesday's market close, IonQ was trading at $41.21 per share. Garrigan's price target is $70, indicating about 70% upside. That's a strong return in a short time frame, but is IonQ stock a buy now? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » IonQ's trapped ion approach shows potential IonQ is a leading quantum computing company, which is impressive considering that it doesn't have another business to fund its operations. IonQ relies on raising capital in the public markets and various contracts it has to fund its research, unlike many of the big tech competitors in this space, which have massive cash flows to fund their quantum computing research. Despite this disadvantage, IonQ has developed impressive quantum computing technology. IonQ has taken the trapped ion approach to quantum computing, which has benefits and drawbacks. On the plus side, trapped ion architecture has impressive fidelity, and IonQ holds the world record in 1-qubit gate fidelity tests. (A qbit, or quantum bit, is the basic unit of information used in quantum computing to encode data.) It can also be done at room temperature, while other solutions need to be cooled to absolute zero. On the downside, trapped ion quantum computing can have a slightly slower processing speed compared to other solutions. Time will tell whether this is a winning approach, but some of IonQ's early successes indicate that it could be viable. But will that be enough to deliver the $70 stock price that Garrigan thinks is possible? IonQ won't see real business gains for at least a few years Any stock price prediction for IonQ is speculation. While it has a handful of contracts and its quantum computing devices are available for use on all three major cloud computing services, there's really no commercial market for quantum computing right now. However, most quantum computing companies point toward 2030 being a key year, and IonQ is no exception. Its CEO projected that IonQ would be profitable and generate sales of nearly $1 billion by 2030. After that, management expects significant market expansion, with an $87 billion market emerging by 2035. To bridge the gap between profitability and its research phase, IonQ has $1.6 billion in cash, cash equivalents, and outside investments, which should allow it to reach this critical point. While it's impossible to know if IonQ's technology will propel it to be a winning quantum computing pick over the next few years, investors can feel confident that IonQ has the proper resources and backing to at least get to that point. Whether that's worth a $70-per-share target is a different question that I can't answer, but with all of the momentum behind quantum computing, I have a hard time seeing this stock slowing down anytime soon. As a result, I think it's worth an investment, as long as the position size is kept relatively small to help manage risk. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
3 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
5 hours ago
- Globe and Mail
2 Soaring Tech Stocks to Buy and Hold for the Next Decade
Key Points Microsoft is well on its way to dethroning Amazon in the ever-expanding cloud market. Oracle's autonomous database business is booming, and it sees further room for growth. 10 stocks we like better than Microsoft › Investors looking for winning stock ideas for the next decade need to look no further than the companies enabling artificial intelligence (AI) adoption. The recent financial results of leading companies serving the cloud computing market show that enterprise investment in AI is still in the early stages. Here are two stocks to profit from this opportunity. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » 1. Microsoft Microsoft (NASDAQ: MSFT) is the 800-pound gorilla in the cloud services market. While Amazon continues to control the top spot in market share, Microsoft Azure is growing faster and is on pace to eventually overtake the No. 1 position in the cloud market. Microsoft stock is up 26% year to date. Azure and other cloud services from Microsoft posted a 39% year-over-year increase in revenue for the fiscal fourth quarter (which ended in June). Management credits its growing footprint of over 400 data centers in 70 regions around the world for its momentum. The company is further bolstering its competitive position with tools like Microsoft Fabric. This is a data and analytics platform that is rapidly expanding. Revenue grew 55% year over year last quarter, indicating that Microsoft is positioned to capture demand for AI-driven database services. Microsoft generates $281 billion in annual revenue right now, yet management noted that there is $368 billion worth of contracted backlog across its cloud business. With a company this large growing earnings per share at 24% year over year in the recent quarter, it's possible that Wall Street is still underestimating the size of the AI opportunity. Analysts are projecting low-double-digit earnings growth over the next few years, but that might be underestimating the company's opportunity. Microsoft has delivered excellent returns for investors for many years, and that streak doesn't appear to be ending anytime soon. 2. Oracle Oracle (NYSE: ORCL) is another top tech stock to ride the growing investment in cloud services. Oracle's Cloud Infrastructure business is experiencing explosive growth, which sent the stock to new highs after its fiscal Q4 earnings report in June. "In Q4, we hit double-digit revenue growth and it's only going up from here," CEO Safra Catz said during the earnings call. Oracle has been building up its cloud offering for over a decade, and it's paying off. Companies are choosing Oracle for its market-leading database services to leverage autonomous features. Autonomous database consumption revenue grew 47% year over year, accelerating from 27% growth in the year-ago quarter. Beginning in fiscal 2026, management expects growth to accelerate. Company guidance calls for total cloud revenue growth to be over 40% in constant currency, with cloud infrastructure growth of over 70%, which includes the autonomous database business. Oracle is playing an important role in enabling the AI revolution across the economy. This is evidenced by its participation in the Stargate Project with OpenAI, which aims to build state-of-the-art AI infrastructure in the U.S. The revenue expected from Stargate should at least marginally contribute to Oracle's growth over the next decade. For what it's worth, Wall Street analysts expect Oracle's adjusted (non-GAAP) earnings to grow at an annualized rate of 19% through fiscal 2030. Oracle is an industry-leading cloud database provider with a large suite of enterprise applications. It has a long history of delivering solid returns to investors, with the stock up over 500% in the last decade. With growth accelerating due to AI, it should continue to reward shareholders. Should you invest $1,000 in Microsoft right now? Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Microsoft, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
